About this trial
Inflammatory bowel disease (IBD) is often comorbid with depressive disorder, and the development and progression of both conditions are closely related to the composition of gut microbiota and metabolites. However, studies investigating their comorbidity using microbiome and metabolomics approaches remain limited.
This study aims to investigate the diversity changes in the gut microbiome and metabolome of patients with comorbid IBD and depressive disorder through multi-omics approaches, to identify specific microbial and metabolic signatures associated with the comorbidity of these two conditions, and to provide a molecular basis for elucidating the underlying mechanisms.
Eligibility criteria
Qualifiers
Patients diagnosed with inflammatory bowel disease (ICD-10 codes: K50-K51).
History of depressive disorder diagnosis or previous use of antidepressant medications.
Age ≥ 18 years.
Willingness to participate and provision of written informed consent.
Disqualifiers
Presence of other major chronic diseases or infections (e.g., malignancy, hypertension, diabetes, coronary heart disease).
Use of antibiotics or probiotic supplements within the past 6 months.
Inability or difficulty in providing biological samples.
Missing essential patient information.
Trial design
Treatments tested in this trial
- Not applicable- observational study
Treatment groups
Sponsors and collaborators
Fang Tang
Lead sponsor
Qianfoshan Hospital
Sponsor institution